Want to see TMO full AI Analyst Report?
TMO Stock Chart & Stats
$526.60
$0.83(0.15%)
At close: 4:00 PM EST
$526.60
$0.83(0.15%)
Day’s Range― - ―
52-Week Range$403.36 - $643.99
Previous CloseN/A
Volume471.20K
Average Volume (3M)2.00M
Market Cap
$197.88B
Enterprise Value$216.59K
Total Cash (Recent Filing)$3.26B
Total Debt (Recent Filing)$43.16B
Price to Earnings (P/E)29.2
Beta0.67
Next Earnings
Jul 23, 2026EPS Estimate
5.72Next Dividend Ex-DateN/A
Dividend Yield0.34%
Share Statistics
EPS (TTM)18.22
Shares Outstanding371,621,460
10 Day Avg. Volume1,646,293
30 Day Avg. Volume1,995,457
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$585.53Price Target Upside11.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)24.85
Revenue Forecast (FY)$47.76B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationConsistent, high free cash flow provides durable strategic optionality: it funds R&D, capital expenditures, dividends, buybacks and M&A while enabling deleveraging. Reliable FCF supports long-term investment and shareholder returns even if organic growth remains modest.
Recurring Consumables And Services Business ModelA platform of instruments plus recurring consumables and service contracts creates durable pull‑through revenue and high customer stickiness. This business mix smooths demand cycles, supports margin sustainability and underpins predictable long‑term cash conversion.
Raised 2026 Guidance And Accretive Clario AcquisitionUpgraded guidance tied to an accretive acquisition signals strategic M&A that meaningfully expands pharma services and commercial scale. If integration sustains margins, the deal improves structural revenue mix and strengthens long‑term service-led growth.
Bears Say
Elevated Leverage After AcquisitionMaterial post‑acquisition leverage reduces financial flexibility and raises refinancing and interest‑rate exposure. Sustained high debt requires consistent FCF and/or asset sales to deleverage, constraining optionality for future investments or buffering downturns.
Muted Multi-year Organic Revenue GrowthA prolonged period of weak organic growth increases reliance on acquisitions and FX to hit targets, limiting operating leverage and return expansion. Without sustained organic acceleration, margin gains and ROIC improvements may be harder to maintain long term.
Governance Risk From Say‑on‑pay RejectionA failed advisory vote can trigger investor activism or tighter oversight, forcing compensation redesigns and taking management bandwidth. Governance friction can complicate retention incentives and investor relations during a period of strategic integration and leverage reduction.
TMO FAQ
What was Thermo Fisher Scientific’s price range in the past 12 months?
Thermo Fisher Scientific lowest stock price was $403.36 and its highest was $643.99 in the past 12 months.
What is Thermo Fisher Scientific’s market cap?
Thermo Fisher Scientific’s market cap is $197.88B.
When is Thermo Fisher Scientific’s upcoming earnings report date?
Thermo Fisher Scientific’s upcoming earnings report date is Jul 23, 2026 which is in 3 days.
How were Thermo Fisher Scientific’s earnings last quarter?
Thermo Fisher Scientific released its earnings results on Apr 23, 2026. The company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.248 by $0.192.
Is Thermo Fisher Scientific overvalued?
According to Wall Street analysts Thermo Fisher Scientific’s price is currently Undervalued.
Does Thermo Fisher Scientific pay dividends?
Thermo Fisher Scientific pays a Quarterly dividend of $0.47 which represents an annual dividend yield of 0.34%. See more information on Thermo Fisher Scientific dividends here
What is Thermo Fisher Scientific’s EPS estimate?
Thermo Fisher Scientific’s EPS estimate is 5.72.
How many shares outstanding does Thermo Fisher Scientific have?
Thermo Fisher Scientific has 371,621,460 shares outstanding.
What happened to Thermo Fisher Scientific’s price movement after its last earnings report?
Thermo Fisher Scientific reported an EPS of $5.44 in its last earnings report, beating expectations of $5.248. Following the earnings report the stock price went down -9.199%.
Which hedge fund is a major shareholder of Thermo Fisher Scientific?
Currently, no hedge funds are holding shares in TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$585.53 (11.19% Upside)
$585.53 (11.19% Upside)
Blogger Sentiment
Bullish
TMO Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.75%
12-Months-Change
Fundamentals
Return on Equity
0.34%
Trailing 12-Months
Asset Growth
14.38%
Trailing 12-Months
Company Description
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
TMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics

TMO Stock 12 Month Forecast
Average Price Target
$585.53
▲(11.19% Upside)
Technical Analysis
Ownership Overview
0.13% Insiders
24.19% Mutual Funds
1.20% Other Institutional Investors
54.07% Public Companies and Individual Investors










